You are here

Development of the GlycoFibrotyper for detection of liver fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK124058-01
Agency Tracking Number: R41DK124058
Amount: $223,055.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA18-575
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-09-17
Award End Date (Contract End Date): 2020-08-31
Small Business Information
4058 BLACKMOOR ST, Mount Pleasant, SC, 29466-7160
DUNS: 117004337
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Danielle Scott
 (540) 229-6207
Business Contact
Phone: (678) 910-3534
Research Institution
 Nonprofit college or university
Increasinglyalterations in N linked glycans have been reported for serum or plasmaor for the most abundant serum glycoproteinimmunoglobulin Gfrom large cohorts of samples representing rheumatoid arthritisdigestive diseasescancer and liver fibrosisIn the case of fibrosistwo tests have identified alterations in Nlinked glycosylation on both total IgG populations and on specific IgG moleculesBoth of these tests can detect significant fibrosis with a high degree of accuracy and are also able to detect intermediate levels of fibrosisHoweverboth tests have drawbacks in that they require specialized sample handling resourcesextensive processing and purification prior to analysisand are expensive in regards to reagents and processingOur group has recently developed a streamlined antibody capture slide array approach to directly profile N glycans of captured serum glycoproteins like IgGa method requiring a few microliters of sample and simplified processing workflows that require no purification or sugar modifications prior to analysisThis parent method is referred to as the GlycoTyperIn this methodN linked glycans are released from antibody captured glycoproteins and are directly analyzed by MALDI TOF mass spectrometrysuch as the Bruker Tissuetyper MALDI TOFwhich is already available in clinical laboratoriesWe hypothesize that this method can be used to identify glycan biomarkers reflective of the changes that occur during the development of many diseasesincluding liver fibrosis cirrhosis as performed here NarrativeThis application will develop a new platform for glycan analysis and determine its ability to detect liver fibrosis

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government